Sei Investments CO Arcus Biosciences, Inc. Transaction History

Sei Investments CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $781,259 - $1.71 Million	-45,343 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $139,278 - $201,453	-4,816 Reduced 9.6%	45,343 $1.43 Million
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $1.57 Million - $2.43 Million	50,159 New	50,159 $2.03 Million
Q3 2020 Nov 06, 2020	SELL	$17.14 - $25.47 $204,617 - $304,060	-11,938 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$13.97 - $36.56 $166,773 - $436,453	11,938 New	11,938 $295,000

207

49M

173K

151K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.11B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

Stay updated on Sei Investments CO with notifications on news.